IceCure Medical Ltd. Announces Positive THERMAC Trial Results for ProSense® Cryoablation in Breast Cancer, Achieving High Patient Satisfaction and Complete Ablation Rates
IceCure Medical Ltd. announced positive results from the THERMAC Trial for its ProSense® cryoablation system in early-stage breast cancer. The trial, conducted in the Netherlands, showed ProSense® achieved the highest complete ablation rates and 95% patient satisfaction regarding cosmetic outcomes. Findings were published in the European Journal of Surgical Oncology and Radiology, indicating ProSense® as a preferred technique for future comparisons with surgery in phase III trials. The results were also presented at major medical conferences.
IceCure Medical Ltd. has announced two new publications from the independent THERMAC Trial featuring its ProSense® cryoablation system for early-stage breast cancer. The trial, conducted in the Netherlands, compared different thermal ablation methods, with ProSense® demonstrating the highest complete ablation rate without adverse events. The first article, published in the European Journal of Surgical Oncology, reported that 95% of patients were satisfied with the cosmetic outcomes of ProSense® cryoablation. The second article, published in Radiology, highlighted its superior performance compared to other thermal ablation techniques. These findings were previously presented at several medical conferences, including the European Conference on Interventional Oncology 2025 and the Society of Interventional Oncology 2025 Annual Meeting. The THERMAC Trial’s phase II results suggest that cryoablation with ProSense® is the preferred technique for future comparisons with surgery in a phase III trial. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO67619) on September 08, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
